- Home
- ICMB vs AKTX Comparison
ICMB vs AKTX Comparison
Compare ICMB & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICMB
- AKTX
- Stock Information
- Founded
- ICMB 2012
- AKTX N/A
- Country
- ICMB United States
- AKTX United States
- Employees
- ICMB N/A
- AKTX N/A
- Industry
- ICMB Finance: Consumer Services
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ICMB Finance
- AKTX Health Care
- Exchange
- ICMB Nasdaq
- AKTX Nasdaq
- Market Cap
- ICMB 41.1M
- AKTX 41.8M
- IPO Year
- ICMB N/A
- AKTX N/A
- Fundamental
- Price
- ICMB $2.75
- AKTX $1.16
- Analyst Decision
- ICMB
- AKTX
- Analyst Count
- ICMB 0
- AKTX 0
- Target Price
- ICMB N/A
- AKTX N/A
- AVG Volume (30 Days)
- ICMB 25.0K
- AKTX 28.0K
- Earning Date
- ICMB 05-13-2025
- AKTX 08-18-2025
- Dividend Yield
- ICMB 17.27%
- AKTX N/A
- EPS Growth
- ICMB N/A
- AKTX N/A
- EPS
- ICMB 0.82
- AKTX N/A
- Revenue
- ICMB $20,996,189.00
- AKTX N/A
- Revenue This Year
- ICMB N/A
- AKTX N/A
- Revenue Next Year
- ICMB N/A
- AKTX N/A
- P/E Ratio
- ICMB $3.37
- AKTX N/A
- Revenue Growth
- ICMB N/A
- AKTX N/A
- 52 Week Low
- ICMB $2.46
- AKTX $0.85
- 52 Week High
- ICMB $3.47
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- ICMB 45.17
- AKTX 44.02
- Support Level
- ICMB $2.75
- AKTX $1.15
- Resistance Level
- ICMB $2.95
- AKTX $1.22
- Average True Range (ATR)
- ICMB 0.11
- AKTX 0.07
- MACD
- ICMB -0.00
- AKTX 0.00
- Stochastic Oscillator
- ICMB 18.00
- AKTX 36.53
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.